Summary of Key Points Core Viewpoint The company is adjusting part of its fundraising projects and changing the use of some raised funds to optimize resource allocation and enhance operational efficiency, which aligns with its strategic development goals and benefits all shareholders [21][22]. Group 1: Fundraising Overview - The company has received approval from the China Securities Regulatory Commission for its initial public offering, raising a total of RMB 340.24 million by issuing 16.11 million shares at RMB 21.12 each [1]. - The funds are stored in a dedicated account, and a tripartite supervision agreement has been signed with the sponsor and the supervising bank [2]. Group 2: Actual Use of Funds - As of May 23, 2025, the company has invested RMB 39.84 million in various projects, with a remaining balance of RMB 11.02 million in unutilized funds [3][5]. - The main projects include the construction of an environmentally friendly water-based printing glue production base and a headquarters and R&D center [3]. Group 3: Adjustments to Fundraising Projects - The company plans to relocate its R&D center to an existing production base to improve management and reduce operational costs while maintaining the same investment amount [6][7]. - The adjustment aims to enhance collaboration between production and R&D, supporting the development of high-performance silicon-based materials [6][7]. Group 4: Changes in Project Investment - The company is merging two projects into one, increasing the annual production capacity from 15,000 tons to 27,750 tons for environmentally friendly water-based printing glue [8][9]. - The total investment for the merged project is set at RMB 20.83 million, with a proposed fundraising amount that matches the previous projects' total [9][10]. Group 5: Economic Benefits and Feasibility - The merged project is expected to generate an average annual sales revenue of RMB 37.72 million, with a financial internal rate of return of 13.75% and a net present value of RMB 2.68 million [12][14]. - The project aligns with national policies promoting green and sustainable development, enhancing the company's competitive edge in the market [15][16]. Group 6: Approval and Compliance - The adjustments have been approved by both the board of directors and the supervisory board, ensuring compliance with relevant regulations and guidelines [21][22]. - The sponsor has confirmed that the adjustments will not harm the interests of the company or its minority shareholders and will not adversely affect current operations [22].

Core Viewpoint - Nanjing New Pharmaceutical Co., Ltd. has announced multiple delays in its fundraising projects, particularly the "Marketing Channel Network Upgrade Project," which has been postponed to December 31, 2026, indicating ongoing challenges in project execution and market competition [1][3][4]. Group 1: Project Delays - The "Marketing Channel Network Upgrade Project" was initially set to be operational by June 30, 2025, but has now been delayed by an additional 18 months [1][3]. - The project aims to establish 8 new offices and upgrade 22 existing ones, with a total investment of 120 million yuan [2]. - The delays are attributed to macroeconomic conditions, industry policies, and a reduced need for new offices due to strategic adjustments [3][4]. Group 2: Termination of Projects - The company has terminated the "Palivizumab Dry Powder Inhalation Project" and redirected the remaining funds of 43.97 million yuan to the "Palivizumab Inhalation Solution Project" [4][5]. - The "Palivizumab Inhalation Solution Project" has also been delayed to December 31, 2026, with an increased funding allocation of 214 million yuan [4][6]. Group 3: Financial Performance - Nanjing New Pharmaceutical has faced significant financial challenges, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, representing a decrease of over 70% [8]. - The company has reported net losses in all years since its IPO, except for the first year, with a net profit of 128 million yuan in 2020 turning into a loss of 357 million yuan in 2024 [8]. - In Q1 2025, the company reported a revenue drop of 70.21% year-on-year, primarily due to lower market demand for antiviral products and price reductions [8]. Group 4: Market Strategy - The company has adopted a price reduction strategy to maintain market share in the competitive antiviral market, with a 43.51% price cut on its core product, Palivizumab, in 2023 [7]. - Despite these efforts, the declining sales and increased competition have not improved the company's financial situation [7][8].

国金证券股份有限公司（以下简称"保荐机构"）为立达信物联科技股份有 限公司（以下简称"立达信"或"公司"）首次公开发行股票并上市的保荐机构， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》《上市公司监管指引第2号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第1号——规范运作》等有关规定，对立达信将部分 募投项目节余募集资金用于其他募投项目及部分募投项目延期的事项进行了核 查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额及到位时间 经中国证券监督管理委员会《关于核准立达信物联科技股份有限公司首次公 开发行股票的批复》 （证监许可〔2021〕2186 号）核准，公司向社会公开发行人 民币普通股（A 股）5,000 万股，每股面值为人民币 1.00 元，发行价格为人民币 万元（不含增值税）后，实际募集资金净额为人民币 77,135.33 万元。 国金证券股份有限公司关于立达信物联科技股份有限公司 将部分募投项目节余募集资金用于其他募投项目及部分募投项 目延期的核查意见 前述 ...

天洋新材（上海）科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 天洋新材（上海）科技股份有限公司（以下简称"公司"）第四届监事会第二十五 次会议于 2025 年 05 月 26 日上午 11 时在公司二楼会议室以现场方式召开，本次会议应 出席监事 3 人，现场实际出席监事 3 人，董事会秘书及证券事务代表列席了本次会议。 会议由公司监事会主席郑晓燕女士主持。本次会议的召开符合《中华人民共和国公司法》 （以下简称"《公司法》"）、《天洋新材（上海）科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，会议合法、有效。 二、 监事会会议审议情况 （一）审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》 证券代码：603330 证券简称：天洋新材 公告编号：2025-042 易所上市公司自律监管指引第 1 号——规范运作》等有关规定，结合 2022 年度非公开发 行募集资金投资项目的资金使用计划和项目的建设进度，公司在确保不影响募集资金投 资项目建设的前提下，为提高 ...

Core Viewpoint - Hefei Jingsong Intelligent Technology Co., Ltd. is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the termination of certain fundraising projects and the revision of the company's governance structure [1][6]. Group 1: Meeting Procedures - The meeting is organized to ensure the orderly conduct and protection of shareholders' rights, with specific guidelines for attendance and participation [1][2]. - Shareholders must present identification and register for the meeting between specified times [2]. - The meeting will include a combination of on-site and online voting, with detailed procedures outlined in prior announcements [3][4]. Group 2: Proposals - Proposal 1 involves terminating the "Intelligent Logistics System Production Base Technical Transformation Project" and reallocating the remaining and unused funds to a new project aimed at producing 10,000 sets of intelligent logistics equipment [4][5]. - Proposal 2 seeks to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors, in accordance with the revised Company Law [6][7]. - Proposal 3 focuses on revising certain corporate governance systems to enhance operational standards, with specific changes requiring shareholder approval [8][9][10].

Core Viewpoint - The company has announced adjustments to its fundraising projects, including changes in investment amounts and the addition of new implementation entities, which are expected to be normal adjustments based on existing resources and market conditions [1][4]. Group 1: Project Adjustments - The total investment for the "Machining Expansion and Component Industry Chain Extension Project" has increased from 56,437.53 thousand yuan to 78,511.92 thousand yuan, with an additional investment of 22,074.39 thousand yuan funded entirely by the company's own funds [2]. - The company will reallocate 1,500.00 thousand yuan of raised funds from the "Intelligent Upgrade of Casting Production Line and R&D Capability Enhancement Project" to the "Machining Expansion and Component Industry Chain Extension Project," supplemented by 1,500.00 thousand yuan from its own funds [2]. - New implementation entities, including Huaxiang Saint Dema (Shanghai) and its wholly-owned subsidiary Huaxiang Automotive Technology Company, will be added alongside existing entities for the execution of the fundraising projects [2]. Group 2: Bond Redemption and Rating - The adjustments have triggered additional redemption clauses for the "Huaxiang Convertible Bonds," allowing bondholders to choose whether to redeem their bonds at a price of 100.58 yuan per bond during the redemption period from May 12 to May 16, 2025 [2][3]. - The company has decided to exercise its right to early redemption of the "Huaxiang Convertible Bonds" due to the stock price meeting the conditions for conditional redemption [3]. - The credit rating agency maintains the company's credit rating at AA- and the outlook at AA-, while closely monitoring the use of raised funds and the progress of the fundraising projects [4].

Meeting Overview - The second meeting of the Supervisory Board of Hefei Jingsong Intelligent Technology Co., Ltd. was held on May 16, 2025, with all three supervisors present, ensuring the meeting's legality and effectiveness [1] Resolutions Passed - The Supervisory Board approved the proposal to use up to RMB 270 million of temporarily idle raised funds and up to RMB 100 million of temporarily idle self-owned funds for cash management, which aims to improve fund utilization efficiency and increase returns [2][3] - The proposal to terminate certain fundraising projects and allocate remaining and unused excess funds to new projects was also approved, deemed a prudent decision aligned with the company's operational needs [2][3] - The resolution to cancel the Supervisory Board and amend the company's articles of association was passed, allowing the Audit Committee of the Board to assume the Supervisory Board's responsibilities [3][4]

Company Overview - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported a revenue of 2.21 billion yuan in 2024, representing a year-on-year increase of 17.35% [27] - The net profit attributable to shareholders reached 651 million yuan, up 36.85% compared to the previous year [27] - The total assets of the company amounted to 5.60 billion yuan, reflecting a growth of 10.08% year-on-year [27] Industry Overview - The expected production of vitamins in China for 2024 is 420,000 tons, a decrease of 3.6% year-on-year, accounting for 85.9% of global production [14] - The market value of the vitamin industry in China is projected to be approximately 3.79 billion USD in 2024, with a growth of 1.4% [14] - Vitamin exports are anticipated to reach 332,000 tons, an increase of 5.6%, with export value expected to be 3.00 billion USD, up 11.1% [14] Company Operations - The company has focused on cost reduction, quality improvement, and efficiency enhancement across its operations, leading to a strengthened competitive position in the vitamin sector [15] - The company has optimized production processes and improved management levels, resulting in increased product yield and cost advantages [15] - The company achieved large-scale production of Vitamin B5 during the reporting period and is steadily advancing other investment projects [15] Corporate Governance - The company has established a governance structure comprising the shareholders' meeting, board of directors, supervisory board, and management, ensuring clear responsibilities and checks and balances [16] - The board of directors has conducted regular training to enhance compliance awareness and performance capabilities among directors and senior management [17] Financial Performance - The operating income for 2024 was 2.21 billion yuan, with a cost of sales of 1.28 billion yuan, leading to a gross profit margin improvement [29] - The company maintained stable expense levels across various categories, with a notable increase in research and development expenses [29][30] Future Outlook - The company plans to enhance product quality research, accelerate high-end market registrations, and explore new growth points in existing products [18] - The company aims to improve its digital transformation and smart manufacturing capabilities to enhance operational efficiency [19]

Core Viewpoint - The report outlines the findings of the on-site inspection conducted by the sponsor institution, CITIC Construction Investment Securities Co., Ltd., on Zhejiang Lianxiang Intelligent Home Co., Ltd., focusing on corporate governance, internal controls, information disclosure, independence, fundraising usage, related transactions, and operational status. Group 1: Corporate Governance and Internal Control - The company has effectively implemented its governance structure, with board meetings and internal regulations being adhered to [2][3] - The internal audit department and audit committee are compliant, and risk assessment measures are effectively executed [2] Group 2: Information Disclosure - The company has strictly followed regulatory requirements for information disclosure, ensuring that all significant information is reported truthfully and accurately [3] Group 3: Independence and Related Party Transactions - The company maintains independence in its operations, with no significant reliance on the controlling shareholder or misuse of funds from related parties [4] Group 4: Fundraising Usage - The company has adjusted its fundraising project allocations due to market conditions, reallocating funds between projects while ensuring compliance with regulatory requirements [5][6] - Specific projects have seen changes in investment amounts and timelines, with the "Annual Production of 350 Million Meters Seamless Wall Cloth Project" and "Wall Material R&D Center Project" being extended to December 31, 2025 [6] Group 5: Related Transactions and External Guarantees - The company has established a regulated decision-making mechanism for related transactions and external guarantees, with no violations or harm to minority shareholders identified [7][8] Group 6: Operational Status - The company continues to operate effectively in the wall cloth and curtain markets, with no significant changes in its business model since its listing [8] Group 7: Rectification Matters - The company has received warnings from regulatory bodies regarding financial disclosures and has taken corrective actions, including submitting rectification reports [9][10] Group 8: Conclusion of the Inspection - The inspection concluded that the company complies with relevant regulations in governance, information disclosure, fundraising usage, and operational practices, with no major issues identified [11]

Group 1 - The company approved the proposal to reappoint Lixin as the auditor for the 2025 financial report and internal control audit [1][2] - The decision was made unanimously by the board with 8 votes in favor and no opposition [2] - The reappointment is subject to approval at the 2024 annual general meeting [2][6] Group 2 - The company announced a profit distribution plan for 2024, proposing a cash dividend of 2.0 yuan per 10 shares, totaling approximately 28.37 million yuan [4][5] - The net profit attributable to shareholders for 2024 is reported at approximately 90.18 million yuan, with distributable profits at approximately 280.52 million yuan [3][4] - The proposed cash dividend represents 42.56% of the net profit attributable to the parent company [5] Group 3 - The company plans to conduct foreign exchange hedging activities to mitigate risks associated with currency fluctuations, with a maximum amount of 300 million yuan or equivalent in foreign currency [10][12] - The hedging activities will involve major currencies such as USD and EUR, using methods like forward contracts and options [15][19] - The board approved the hedging proposal without requiring shareholder approval [20] Group 4 - The company provided a guarantee of 70 million yuan for its wholly-owned subsidiary, Wenzhou Weigang International Trade Co., Ltd., to support its bank credit needs [30][31] - The guarantee is valid for 12 months and can be reused within the approved limit [30][31] - The total amount of guarantees provided by the company is 70 million yuan, which accounts for 6.11% of the latest audited net assets [34] Group 5 - The company announced adjustments to the construction content of its fundraising project for a new production line, maintaining the total investment amount [35][45] - The project aims to enhance resource efficiency and ensure smooth implementation, with expected annual output value of approximately 79.24 million yuan [41][45] - The adjustments were approved by both the board and the supervisory committee and will be submitted for shareholder approval [46][48]